AbbVie Inc (ABBV)vsCoya Therapeutics, Inc. Common Stock (COYA)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
COYA
Coya Therapeutics, Inc. Common Stock
$4.38
-3.10%
HEALTHCARE · Cap: $106.03M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 802808% more annual revenue ($64.39B vs $8.02M). ABBV leads profitability with a 9.8% profit margin vs -270.2%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
COYA
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
-13.6%
Fair Value
$4.34
Current Price
$4.38
$0.04 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 49.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : COYA
The strongest argument for COYA centers on Revenue Growth, Price/Book. Revenue growth of 49.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : COYA
The primary concerns for COYA are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while COYA is a hypergrowth play — different risk/reward profiles.
COYA carries more volatility with a beta of 0.60 — expect wider price swings.
COYA is growing revenue faster at 49.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 29/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Coya Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is headquartered in Houston, Texas.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?